Navigation Links
Angiotech announces director resignation
Date:4/15/2008

VANCOUVER, April 15 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced the resignation of Greg Peet from his position as a non-executive director of the Company. Mr. Peet has resigned to enable him to focus on his numerous business pursuits and additional board appointments. Mr. Peet has served on Angiotech's Board of Directors since 2005. This position will not be replaced at the current time and the remaining six directors will continue to carry out the duties of the board.

"The board and management would like to thank Greg for his many contributions to the Company's development," said David Howard, Angiotech's Chairman of the Board. "We wish him well in his future endeavours."

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
2. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
3. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
4. Angiotech to participate in Lehman Brothers Healthcare Conference
5. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
6. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
7. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
8. Angiotech announces results for the fourth quarter ended December 31, 2007
9. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
11. Angiotech and Symphony Medical Announce Licensing Agreement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...G, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Lt...cines, announced today that it executed,a joint ve... Vaccine,Technology Co., Ltd. (Sinovac Dalian). Th...lize human-use vaccines. Sinovac will contribute i...ercializing world-class vaccines; the,other party ...
(Date:11/25/2009)...25 Ardea Biosciences, In...Quart, Pharm.D., president and chief executive off...l Health Care Conference. , ,Presentation details... Care Conference,Date: Tuesday, December 1, 2...he New York Palace Hotel, New York, NY,Webcast: ...
(Date:11/24/2009)... 24 IES (Nasdaq: IESC )...mmunications systems and services for the commerci...today that its commercial business group has been ...tall the electrical systems for the Level 4 bio-sa...Army Medical Research Institute of Infectious Dise...
(Date:11/24/2009)... New York investment bank KTA Capital,s client Neu...$6.7 mil convertible note private placement with a...t was arranged by KTA Capital as Neuren,s exclusiv... New York (PRWEB) November 23, 2009 -- The ...LLC ("KTA Capital") has announced that i...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...ts from a,clinical study comparing INVEGA(TM) (pal...(marketed as Seroquel(R)) and placebo in patients ...ill be the subject of a poster,on display during t...Congress, which takes place October 11-14, 2007 in...ve Analysis of Paliperidone ER and,Quetiapine in P...
... to benefit from rapid, long-lasting symptom cont... formoterol fumarate -, NAPA,...Inc. (NYSE: MYL ), today announced the launch of ...olution, which will be available,nationwide throug...ilities,and home healthcare companies. Perforomist...
...s Stem Cell Treatment Hospital with Clear ...NG, Oct. 8 Tiantan Puhua Neurosurgical,Hospital, ... of Parkinson,s,disease using adult retinal stem c...ional patients returned home from China with a sig...,s disease symptoms. These success,stories clearly...
Other Biology Technology:Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 2Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 3Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 2American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 3American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot 4
(Date:11/26/2009)...logists have at last worked out a way of using rec... of bird populations. This is the first time sound...slated into accurate estimates of bird species, po...the British Ecological Society,s Journal of Appli...uld lead to a major advance in our ability to moni...
(Date:11/25/2009)...ADENA, Calif.Scientists at the California Institut...of a primitive emotion-like behavior in the fruit ..., which may be relevant to the relationship betwee...cit hyperactivity disorder (ADHD), are described i...The Drosophila brain contains only about 20,000 ...
(Date:11/25/2009)...ISON, WI, NOVEMBER 25, 2009 Soil is the linchpin ...nd hydrosphere meet. Despite that, many students s...t nothing more. Soil science educators are challen...ic recognize the critical importance of soil in th...l science and earth science teachers at University...
Breaking Biology News(10 mins):Ecologists sound out new solution for monitoring cryptic species 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4It's not just dirt! 2The Doctor Will See You Now Online 62045 1The Doctor Will See You Now Online 62045 2US Patent Allowed for NOD Tech 14964 1Biolaxy Secures IND Approval for Oral Insulin 14962 1Biolaxy Secures IND Approval for Oral Insulin 14962 2
...ess of human neurons may have been a key factor in...our primate relatives. In a study comparing the ge...brates, researchers at the U.S. Department of Ener...ey Lab) and Joint Genome Institute (JGI) found a s...A sequences that appear to regulate genes involved...
...rceptions about radiation therapy can strongly inf... external beam radiation therapy, even though stud...fective as other treatments for the disease, inclu...ber 5, 2006, at the American Society for Therapeut... Philadelphia. , "The study shows that patients ba...
...at Duke University Medical Center have visualized ...ical process to dice and splice genetic material t...sts say the findings, made in mice, help explain a...ound in every cell of an individual’s body can pro...rgans. These varied proteins, in turn, dictate the...
Other Biology News:Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4Men with prostate cancer avoid radiation due to misconceptions 2Living view in animals shows how cells decide to make proteins 2Living view in animals shows how cells decide to make proteins 3
GENOMIPHI HY KIT 1000 RXN from GE Healthcare, formerly Amersham Biosciences
N-terminal Sequencing from Primm Biotech, Inc.
Japanese medaka Vitellogenin Standard from Cayman Chemical
I-SAGE Ditag PCR Module* from Invitrogen
Biology Products: